Digitek digoxin is a prescription treatment for congestive heart failure and heart rhythm irregularity conditions. A manufacturer's error caused a batch of the drug to be released with double the appropriate dosage of medication, creating a potentially harmful toxicity risk.
Digoxin, also known as Digitalis, Lanoxin, Digitek, and Lanoxicaps, is a refined plant extract, a purified cardiac glycoside (drugs used in the treatment of congestive heart failure and arrythmia). Digoxin is commonly marketed under the names Lanoxin, Digitek, and Lanoxicaps.
It has been manufactured widely in the United States by the pharmaceutical company Actavis Totowa LLC, formerly known as Amide Pharmaceutical, Inc., the New Jersey headquartered and United States based manufacturing division of the international pharmaceutical company Actavis Group. Actavis Group prides itself on being a well known manufacturer and distributor of generic versions of previously name-brand drugs.
Digoxin is widely used in the treatment of various heart conditions, namely atrial fibrilation and atrial flutter, both abnormal heart rhythms It is sometimes prescribed for heart failure that cannot be controlled by other medication. Antiarrhythmic agents are a group of pharmaceuticals that are used to suppress cardiac arrhythmias, such as atrial fibrillation, atrial flutter, ventricular tachycardia and ventricular fibrillation.
While the use of anti-arrhythmic agents to suppress atrial arrhythmia is still in practice, it is unclear whether suppression of atrial arrhythmia will prolong life. It was believed that following a heart attack, suppression of arrhythmia would prolong life, however large clinical trials found that suppression of these arrhythmia would paradoxically increase mortality. This may happen due to the pro-arrhythmic effect these drugs could potentially create in the patient.
The use of digoxin in heart problems during sinus rhythm(normal heart beat)was once standard, but is now controversial. While it appears that the increased force of contraction should lead to improved pumping function of the heart, its effect on prognosis is questionable; additionally, other effective treatments are available, making the use of the medication during sinus rhythm an unnecessary risk. Often, digoxin is not prescribed or thought of as the ideal or first choice for fighting heart failure among patients. It is no longer considered an ideal treatment because it was cited to have no effect on heart conditions or deaths among congestive heart failure patients. It has been shown to increase quality of life in some cases.
Not only is digoxin available as an oral prescription, intravenous injection may be used as well. The half life is about 36 hours; it is given once daily, usually in 125 ¼g or 250 ¼g dosing. For individuals suffering from decreased kidney function, the drug requires a reduced dosage or may need a change of prescriptions.
Common digoxin side effects can include: loss of appetite, nausea, vomiting, diarrhea, blurred vision, visual disturbances (yellow-green halos), confusion, drowsiness, dizziness, nightmares, agitation, and/or depression. Less frequent adverse effects include: acute psychosis, delirium, amnesia, and the possibility of life-threatening heart complications, including additional arrythmia episodes and heart failure. As far as overdose situations are concerned, Digoxin has been shown to increase risk of deadly overdose.
Medical Journal Finds NSAIDs Offer More Harm Than Good to Heart Failure Patients
Recently, a medical journal discovered more harmful side effects among patients consuming nonsteroidal anti-inflammatory drugs (NSAIDs) than helpful side effects among heart failure patients.
Peanut Butter Recall Sickens Hundreds, Criminal Investigation Underway
The recent peanut butter recall has resulted in nearly 600 illnesses and at least eight fatalities, prompting a criminal investigation by government officials. Despite ongoing recalls, the contaminated peanut butter continues to pose a significant health risk to many Americans.
Researchers Study Toxicity Levels of Mesothelioma Treatments
Researchers are attempting to increase the validity of mesothelioma treatments among patients suffering from the fatal condition by testing the highest dosage levels that can be administered to patients without resulting in toxicity levels among individuals.
